echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Not willing to lag behind, Sanofi is a new generation of oral small molecule tumor immunotherapy

    Not willing to lag behind, Sanofi is a new generation of oral small molecule tumor immunotherapy

    • Last Update: 2015-08-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Biovalley, August 11, 2015, tumor immunotherapy is a new treatment method in the field of tumor therapy It can resist cancer by enhancing the immune function of human body, and the most remarkable one is PD-1 / PD-L1 checkpoint inhibitor, which is a kind of injection antibody drug, by blocking PD-1 / PD-L1 The signal pathway makes cancer cells die, has the potential to treat various types of tumors, and is expected to substantially improve the survival of patients At present, the PD-1 / PD-L1 immune competition is extremely fierce, with a peak market value of US $35 billion The leading players in this field include Bristol Myers Squibb, MSD, Roche and AstraZeneca Among them, Bristol Myers is the king Its PD-1 immunotherapy opdivo has received 5 approvals in the three major markets of the United States, Japan and Europe so far, and meytruda has received 2 approvals in the United States and Europe Atezolizumab and AstraZeneca medi4736 are still in phase III clinical practice, and no indications have been obtained Sanofi, the French pharmaceutical giant who missed the game, signed an agreement of US $1.8 billion with its partner regeneron at the end of last month, announcing that it will enter the field of PD-1 / PD-L1, and the two sides will jointly develop PD-1 immunotherapy regn2810 and other new antibody tumor immunotherapy However, at present, PD-1 / PD-L1 field is relatively crowded, while regn2810 is still in phase I clinical practice, and its prospect is not optimistic Of course, Sanofi, as the world's top 10 pharmaceutical giants, is reluctant to follow other giants Recently, the company announced an alliance with German biopharmaceutical company evotec and Austrian biotechnology company apeiron biology to develop a new generation of tumor immunotherapy based on small molecules for the potential treatment of solid tumors and blood cancers This kind of new therapy is expected to enhance the anti-tumor ability of the immune system by oral administration in the form of tablets, which will supplement the tumor immunotherapy of the inhibitors of checkpoints on the market This cooperation is based on the preliminary results of phenotype high-throughput screening conducted by apeiron and evotec Under the terms of the agreement, Sanofi will have the right to screen the internal compound library to identify small molecule candidate drugs suitable for clinical development In addition, Sanofi will provide research funding for evotec and apeiron for two years, and evotec will be eligible for further development, regulatory and commercialization milestones totalling up to 200 million euros ($219 million) Sanofi is solely responsible for all development, regulatory, commercial and production activities In addition to collaborating on new oral tumor immunotherapies, Sanofi also teamed up with evotec over the weekend to develop new therapies for diabetes using stem cells, including beta cell replacement therapy, and regulatory new diabetes drugs that activate beta cells, which are expected to reduce or eliminate the need for insulin injections (read: Sanofi and evotec We have reached hundreds of millions of cooperation to develop new therapies for diabetes using stem cells.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.